The new COVID-19 antibody treatment, Bamlanivimab, is now being used for qualified patients at Fort Hamilton Hospital.
The Food and Drug Administration gave emergency use authorization of the antibody Bamlanivimab. Kettering Health Network began using the new antibody treatment for patients at Kettering Medical Center in November. Patients may be eligible for the infusion treatment if they are suffering from moderate symptoms of COVID-19 including, but not limited to
Based on results in clinical trials, this treatment helps prevent hospital admissions or trips to the emergency department and reduce the risk of disease progression.
“By using Bamlanivimab, we hope to help more patients avoid hospital stays,” says Jeffrey Weinstein, MD, patient safety officer for Kettering Health Network. “As the pandemic continues, Kettering Health Network is committed to using new and innovative ways to treat our COVID-19 patients.”
A physician referral is needed for this treatment, and primary care or emergency department providers will determine if a patient qualifies.